natgillin/translations-raw huggingface dataset:
In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm.
V tem preskušanju so bili v kraku AT pogostejši kot v kraku AC: huda nevtropenija (90 % v prim. z 68,6 %), febrilna nevtropenija (33,3 % v prim. z 10 %), okužbe (8 % v prim. z 2,4 %), driska (7,5 % v prim. z 1,4 %), astenija (8,5 % v prim. z 2,4 %) in bolečine (2,8 % v prim. z 0 %).
In this study, Exjade was compared with placebo (a dummy treatment) and the main measure of effectiveness was the change in iron levels in the liver after 12 months of treatment.
V tej študiji so zdravilo Exjade primerjali s placebom (zdravilom brez zdravilne učinkovine), glavno merilo učinkovitosti pa je bila sprememba ravni železa v jetrih po 12 mesecih zdravljenja.
In this study, forty-six (43%) patients received G-CSF over 192 (42.1%) courses; sixty-five (60%) received transfusions of Packed Red Blood Cells and fifty (46%) of platelets over 139 and 159 courses (30.5% and 34.9%) respectively.
V tej študiji je 46 (43 %) bolnikov prejelo G-CSF v 192 (42,1 %) ciklusih, 65 (60 %) bolnikov je prejelo transfuzije koncentriranih eritrocitov v 139 (30,5 %) ciklusih in 50 (46 %) bolnikov je prejelo transfuzijo trombocitov v 159 (34,9 %) ciklusih.
In this study, Galafold was found to be as effective as enzyme replacement in stabilising patients’ kidney function.
V tej študiji se je zdravilo Galafold pri stabiliziranju delovanja ledvic bolnikov izkazalo za enako učinkovito kot encimsko nadomestno zdravljenje.
In this study, Intelence was not compared with another treatment and the children also took at least two other anti-HIV medicines.
V tej študiji zdravila Intelence niso primerjali z nobenim drugim zdravilom, otroci pa so jemali še vsaj dve drugi zdravili za zdravljenje okužbe z virusom HIV.
In this study, neither superiority nor non-inferiority to placebo + OBT were demonstrated although there was no adverse outcome on viral load or CD4+ cell count.
Ta študija ni dokazala ne superiornosti ne neinferiornosti placeba + OOT, čeprav ni bilo neželenih izidov, kar zadeva virusno breme ali število celic CD4+.
In this study, only chemotherapy-naive subjects, not receiving additional chemotherapy after surgery, were treated with low cumulative dose of epirubicin, i.e. up to 300 mg/m2.
V tej študiji so z majhnim kumulativnim odmerkom epirubicina, t.j. do 300 mg/m2, zdravili samo preskušance, ki predhodno niso prejeli kemoterapije in tudi ne dodatne kemoterapije po operaciji.
In this study, patients given Sovaldi together with ribavirin for 12 weeks were compared with patients given peginterferon alfa and ribavirin for 16 weeks.
V tej študiji so bolnike, ki so 12 tednov prejemali zdravilo Sovaldi v kombinaciji z ribavirinom, primerjali z bolniki, ki so 16 tednov prejemali peginterferon alfa in ribavirin.
In this study, patients received Revestive or placebo (a dummy treatment) every day for 24 weeks.
V tej študiji so bolniki 24 tednov dnevno prejemali zdravilo Revestive ali placebo (zdravilo brez zdravilne učinkovine).
In this study, patients treated with alirocumab who developed ADA had a lower incidence of injection site reactions compared with patients who did not develop ADA (8.6% vs 16.2%).
V tej študiji je bila pojavnost reakcij na mestu injiciranja manjša pri tistih bolnikih, zdravljenih z alirokumabom, ki so se jim pojavila ADA, kot pri bolnikih, ki se jim niso pojavila ADA (8,6 % v primerjavi s 16,2 %).
In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule.
V tej študiji, so bolnikom glede na njihovo starost predpisali shemo titriranja dnevnega odmerka peroralne raztopine po 20 mg/kg, 25 mg/kg, 40 mg/kg ali 50 mg/kg.
In this study, PR interval of > 200 msec was also observed in 40% and 47% of subjects receiving Invirase/ritonavir 1000/100 mg twice daily and 1500/100 mg twice daily, respectively, on Day 3.
Na dan 3 so v tej študiji opazili tudi interval PR > 200 msek pri 40 % posameznikov, ki so prejemali zdravilo Invirase/ritonavir 1000/100 mg dvakrat na dan in pri 47 % posameznikov, ki so prejemali zdravilo Invirase/ritonavir 1500/100 mg dvakrat na dan.
In this study, PR interval of > 200 msec was also observed in 40% and 47% of subjects receiving Invirase/ritonavir 1000/100 mg twice daily and 1500/100 mg twice daily, respectively, on Day 3.
Na dan 3 so v tej študiji opazili tudi intervala PR > 200 msek pri 40 % posameznikov, ki so prejemali zdravilo Invirase/ritonavir 1000/100 mg dvakrat na dan in pri 47 % posameznikov, ki so prejemali zdravilo Invirase/ritonavir 1500/100 mg dvakrat na dan.
In this study, slow acetylators experienced more adverse reactions than the fast acetylators.
V tej študiji so imele osebe s počasno acetilacijo več neželenih učinkov kot osebe s hitro acetilacijo.
In this study, Sprimeo HCT in doses from 150 mg/12.5 mg to 300 mg/25 mg produced dose-dependent blood pressure reductions (systolic/diastolic) from 17.6/11.9 mmHg to
V tej študiji je zdravilo Sprimeo HCT v odmerkih od 150 mg/12,5 mg do 300 mg/25 mg povzročilo od odmerka odvisno znižanje krvnega tlaka (sistoličnega/diastoličnega) od 17,6/11,9 mmHg do 21,2/14,3 mmHg glede na odmerek, v primerjavi z znižanjem za 7,5/6,9 mmHg pri uporabi placeba.
In this study, the adverse events reported were similar to those seen in previous studies in adults with plaque psoriasis.
Poročani neželeni učinki v študiji so bili podobni neželenim učinkom, poročanim v študijah psoriaze s plaki pri odraslih.
In this study, the majority of patients (79%) mixed their short acting insulin with NPH insulin immediately prior to injection and 58% of subjects used oral hypoglycemic agents at randomization and were instructed to continue to use them at the same dose.
Večina bolnikov (79 %) v tej študiji je kratkodelujoči insulin tik pred injiciranjem zmešala z insulinom NPH, 58 % preiskovancev pa je ob randomizaciji uporabljalo peroralne antidiabetike in so dobili navodilo, naj jih v enakem odmerku uporabljajo še naprej.
In this study, the majority of patients (79%) mixed their short acting insulin with NPH insulin immediately prior to injection and 58% of subjects used oral hypoglycemic agents at randomization and were instructed to continue to use them at the same dose.
Večina bolnikov (79 %) v tej študiji je kratkodelujoči insulin tik pred injiciranjem zmešala z insulinom NPH, 58% preiskovancev pa je ob randomizaciji uporabljalo peroralne antidiabetike in so dobili navodilo, naj jih v enakem odmerku uporabljajo še naprej.
In this study, the median patient age was 49 years (range 23-83); 60% were females.
V tej študiji je bila mediana starost bolnikov 49 let (razpon 23–83); 60 % je bilo žensk.
In this study, the median TTP was 34.0 weeks (95% CI = 22.0 – 46.0 weeks).
V tej študiji je bil mediani čas do napredovanja tumorja (TTP – time to tumor progression) 34,0 tedna (95 % IZ: 22,0-46,0 tedna).
In this study, the patients’ condition at the accident scene was compared with that at the end of the infusion of Cyanokit and over the following three days.
V tej študiji so primerjali stanje bolnikov na mestu nezgode s stanjem po koncu infundiranja zdravila Cyanokit ter stanjem v naslednjih treh dneh.
In this study, the primary measure of efficacy was the change from baseline in the total score of the Unified Parkinson’s Disease Rating Scale (UPDRS, parts I-III).
V tej študiji je bilo primarno merilo učinkovitosti doseženo število točk glede na izhodišče na Združeni ocenjevalni lestvici Parkinsonove bolezni (Unified Parkinson's Disease Rating Scale - UPDRS, deli I-III).
In this study, the primary measure of efficacy was the change from baseline in the total score of the Unified Parkinson’s Disease Rating Scale (UPDRS, parts I-III).
V tej študiji je bilo primarno merilo učinkovitosti doseženo število točk, glede na izhodišče na Združeni ocenjevalni lestvici Parkinsonove bolezni (Unified Parkinson's Disease Rating Scale - UPDRS, deli I-III).
In this study, the time to 20 % of total AUC and the AUC (0-2h) representing the early glucose lowering activity were respectively of 114 minutes and 427 mg/kg for insulin glulisine, 121 minutes and 354 mg/kg for lispro, 150 minutes and 197 mg/kg for regular human insulin (see figure 2).
V tej študiji sta bila čas do 20 % celotne AUC in AUC (0–2h), ki predstavljata zgodnji učinek na znižanje glukoze, pri insulinu glulisin 114 minut in 427 mg.kg-1, pri insulinu lispro 121 minut in 354 mg.kg-1 in pri navadnem humanem insulinu 150 minut in 197 mg.kg-1 (slika 2).
In this study, the time to 20% of total AUC and the AUC (0-2h) representing the early glucose lowering activity were respectively of 114 minutes and 427 mg/kg for insulin glulisine, 121 minutes and 354 mg/kg for lispro, 150 minutes and 197 mg/kg for regular human insulin (see figure 2).
V tej študiji sta bila čas do 20 % celotne AUC in AUC (0–2h), ki predstavljata zgodnji učinek na znižanje glukoze, pri insulinu glulisin 114 minut in 427 mg.kg-1, pri insulinu lispro 121 minut in 354 mg.kg-1 in pri navadnem humanem insulinu 150 minut in 197 mg.kg-1 (slika 2).
In this study, two methods were used to classify renal function: the urinary creatinine clearance measured over 24 hours and the creatinine clearance estimated by Cockcroft-Gault formula.
V tej študiji so uporabljali dve metodi za razvrščanje delovanja ledvic: očistek kreatinina v urinu, merjen v obdobju, daljšem od 24 ur, in očistek kreatinina, ocenjen s Cockcroft-Gaultovo formulo.
In this study, Tysabri is not compared with any other treatment.
V tej študiji zdravila Tysabri ne primerjajo z nobenim drugim zdravilom.
In this study, when used to treat bleeding, Voncento was rated excellent in 60.4% (396 out of 656) of the bleeding events and good in 36.0% (236 out of 656) of the bleeding events.
V tej študiji je bilo zdravilo Voncento, kadar so ga uporabili za zdravljenje krvavitev, ocenjeno kot odlično pri 60,4 % (396 od 656) epizod krvavitev in kot dobro pri 36,0 % (236 od 656) epizod krvavitev.
In this study, where patients were followed up for at least 6 months, around 32% (38 out of 120) of patients given Opdivo responded to treatment and had a reduction in their tumours compared with about 11% (5 out of 47) of patients given investigator’s choice of treatment (dacarbazine or a combination of carboplatin and paclitaxel).
V tej študiji, v kateri so bolnike spremljali vsaj šest mesecev, se je približno 32 % (38 od 120) bolnikov, ki so prejemali zdravilo Opdivo, odzvalo na zdravljenje, saj so se njihovi tumorji zmanjšali, v primerjavi s približno 11 % (5 od 47) bolnikov, ki so prejemali zdravljenje, ki ga je izbral raziskovalec (dakarbazin ali kombinacijo karboplatina in paklitaksela).
In this study, Zenapax was added to the children’s existing immunosuppressive medicines.
V tej študiji so zdravilo Zenapax dodajali obstoječim imunosupresivnim zdravilom.
In this subgroup, the incidence of major bleeding on fondaparinux and enoxaparin at Day 9 was 2.2% and 5.0% respectively (hazard ratio 0.43, 95% CI, 0.33;0.57).
bolnikih, ki so prejemali fondaparinuks 2,2 %, pri bolnikih, ki so prejemali enoksaparin pa 5,0 % (razmerje tveganja 0,43, 95 % interval zaupanja, 0,33;0,57).
In this total population, Kaplan-Meier estimates of survival were 93% and 84% 1 and 2 years after the start of treatment with bosentan, respectively.
V tej skupni populaciji je bila po 1 letu zdravljenja z bosentanom ocena preživetja po metodi Kaplan-Meier 93-odstotna, po 2 letih zdravljenja pa 84- odstotna.
In this trial the mean volume of distribution at steady state was 47 ml/kg, mean residence time was 15.5 days and mean clearance was
V tem preskušanju je bil povprečni volumen porazdelitve v stanju dinamičnega ravnovesja 47 ml/kg, povprečni rezidenčni čas 15,5 dneva in povprečni očistek 0,13 ml/kg.
In this trial with demonstrated ability to detect small effects, the upper bound of the one- sided 95% confidence interval for the largest placebo-adjusted, baseline-corrected QTcF was below 10 msec, the threshold for regulatory concern.
V tem preskušanju z dokazano sposobnostjo zaznavanja majhnih učinkov je zgornja meja enostranskega 95-odstotnega intervala zaupanja za največji, s placebom prilagojeni in glede na izhodišče popravljeni interval QTcF pod 10 ms, tj. vrednostjo, ki predstavlja mejo za skrb z vidika ureditev.
In this trial, 10 patients (homozygous for F508del-CFTR mutation) completed dosing with lumacaftor alone 400 mg q12h for 28 days followed by the addition of ivacaftor 250 mg q12h for an additional 28 days, and 25 patients (homozygous or heterozygous for F508del) completed dosing with placebo.
V tem preskušanju je 10 bolnikov (homozigotnih za mutacijo F508del-CFTR) dokončalo odmerjanje samo z lumakaftorjem 400 mg na 12 ur 28 dni, ki mu je sledil dodatek ivakaftorja 250 mg na 12 ur dodatnih 28 dni, 25 bolnikov (homozigotnih ali heterozigotnih za F508del) pa je dokončalo odmerjanje s placebom.
In this trial, 1002 patients were randomised in a 2x2 factorial design to one of the following 4 arms:
V tem preskušanju sta bila bolnika randomizirana v eno od naslednjih štirih skupin po 2x2 faktorskem načrtu:
In this trial, 1987 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3- week cycles for 24 weeks) or 5-FU and leucovorin (Mayo Clinic regimen: 20 mg/m2 leucovorin IV followed by 425 mg/m2 intravenous bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks).
V tem preskušanju so randomizirali 1.987 bolnikov v zdravljenje s kapecitabinom (1.250 mg/m2 dvakrat na dan 2 tedna, sledil je enotedenski premor, dobili so 3-tedenske cikluse v 24 tednih) ali s 5-FU in levkovorinom (shema Mayo: 20 mg/m2 levkovorina intravensko, sledilo je 425 mg/m2 5-FU v obliki intravenskega bolusa vsakih 28 dni – na prvi do peti dan 24 tednov).
In this trial, 1987 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3- week cycles for 24 weeks) or 5-FU and leucovorin (Mayo Clinic regimen: 20 mg/m2 leucovorin IV followed by 425 mg/m2 IV bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks).
V tem preskušanju so randomizirali 1.987 bolnikov v zdravljenje s kapecitabinom (1.250 mg/m2 dvakrat na dan 2 tedna, sledil je enotedenski premor, dobili so 3-tedenske cikluse v 24 tednih) ali s 5-FU in levkovorinom (shema Mayo: 20 mg/m2 levkovorina intravensko, sledilo je 425 mg/m2 5-FU v obliki intravenskega bolusa vsakih 28 dni- na prvi do peti dan 24 tednov).
In this trial, 1987 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles for 24 weeks) or 5-FU and leucovorin (Mayo Clinic regimen: 20 mg/m2 leucovorin intravenous followed by 425 mg/m2 intravenous bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks).
V tem preskušanju so randomizirali 1.987 bolnikov v zdravljenje s kapecitabinom (1.250 mg/m2 dvakrat na dan 2 tedna, sledil je enotedenski premor, dobili so 3-tedenske cikluse v 24 tednih) ali s 5-FU in levkovorinom (shema Mayo: 20 mg/m2 levkovorina intravensko, sledilo je 425 mg/m2 5-FU v obliki intravenskega bolusa vsakih 28 dni – na prvi do peti dan 24 tednov).
In this trial, sixty six percent of the patients (686 out of 1,040) received at least one shortened infusion of 90 minutes or less and 44% of the patients (454 out of 1,040) received at least one shortened infusion of 60 minutes or less.
V tem preskušanju je 66 % bolnikov (686 od 1040) prejelo najmanj eno skrajšano infuzijo v trajanju 90 minut ali manj, 44 % bolnikov (454 od 1040) pa je prejelo najmanj eno skrajšano infuzijo v trajanju 60 minut ali manj.
In this trial, sixty six percent of the patients (686 out of 1,040) received at least one shortened infusion of 90 minutes or less and 44% of the patients (454 out of 1,040) received at least one shortened infusion of 60 minutes or less.
V tem preskušanju je 66 % bolnikov (686 od 1040-tih) prejelo najmanj eno skrajšano infuzijo v trajanju 90 minut ali manj, 44 % bolnikov (454 od 1040-tih) pa je prejelo najmanj eno skrajšano infuzijo v trajanju 60 minut ali manj.
In this trial, the initial rechallenge administration was at a low dose and a lower infusion rate (1/2 the therapeutic dose at 1/25 the initial standard recommended rate).
V tem preskušanju so začetno ponovno izzivalno dajanje izvajali ob manjšem odmerku in manjši hitrosti infundiranja (1/2 terapevtskega odmerka pri 1/25 začetne standardno priporočene hitrosti).
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: < 20 kg, 20 - 40 kg, and > 40 kg.
V tem preskušanju sta polnilni in vzdrževalni odmerek leflunomida temeljila na treh kategorijah telesne mase: < 20 kg, od 20 do 40 kg in > 40 kg.
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: < 20 kg, 20-40 kg, and > 40 kg.
V tem preskušanju sta polnilni in vzdrževalni odmerek leflunomida temeljila na treh kategorijah telesne mase: < 20 kg, od 20 do 40 kg in > 40 kg.
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: <20 kg, 20-40 kg, and >40 kg.
V tem preskušanju sta polnilni in vzdrževalni odmerek leflunomida temeljila na treh kategorijah telesne mase: < 20 kg, od 20 do 40 kg in > 40 kg.
In this trial, the median levels of serum vitamin E, ALA, linoleic acid, EPA, DHA, and arachidonic acid decreased from baseline to Week 26 but remained above the lower limit of the reference range.
V tem preskušanju so se povprečne ravni vitamina E, ALA, linolne kisline, EPA, DHA in arahidonske kisline v serumu od izhodišča do 26 tedna znižale, vendar so ostale nad spodnjo mejo referenčnega razpona.
In this trial, there were two primary objectives: to show that XELOX was non-inferior to FOLFOX-4 and to show that Avastin in combination with FOLFOX-4 or XELOX chemotherapy was superior to chemotherapy alone.
V tem preskušanju sta bila primarna cilja dva: pokazati, da je shema XELOX neinferiorna shemi FOLFOX-4, in da je zdravilo Avastin v kombinaciji s kemoterapevtskima shemama FOLFOX-4 ali XELOX superiorno samostojni kemoterapiji.
In this type of surgery, Inductos can be used instead of an autogenous bone graft (bone taken from one part of a person’s body and placed in another part of the body).
Pri tej vrsti kirurškega posega se lahko zdravilo Inductos uporablja namesto avtogenega kostnega presadka (kosti, odvzete iz enega dela telesa in presajene v drug del istega telesa).
In this younger group of patients, adjunctive therapy with Diacomit should only be started when the diagnosis of SMEI has been clinically confirmed (see section 5.1).
V tej skupini mlajših bolnikov se lahko dodatno zdravljenje z zdravilom stiripentola začne šele, ko je diagnoza SMEI klinično potrjena (glejte poglavje 5.1).
In those cases, sevelamer crystals appeared to have been associated with several non-listed gastrointestinal events such as colitis, ulcer, necrosis and peritonitis.
V teh primerih so bili kristali sevelamerja povezani s hudimi učinki na prebavilih, ki do sedaj niso bili navedeni, npr. s kolitisom, ulkusom, nekrozo in peritonitisom.
In those clinical trials, undesirable effects reported with equal frequency in cancer patients treated with filgrastim/chemotherapy and placebo/chemotherapy included nausea and vomiting, alopecia, diarrhoea, fatigue, anorexia (decreased appetite), mucosal inflammation, headache, cough, rash, chest pain, asthenia, pharyngolaryngeal pain (oropharyngeal pain) and constipation .
V teh kliničnih preskušanjih so bili neželeni učinki, o katerih so z enako pogostnostjo poročali pri rakavih bolnikih, zdravljenih s filgrastimom/kemoterapijo in placebom/kemoterapijo, navzea in bruhanje, alopecija, driska, utrujenost, anoreksija (zmanjšan apetit), vnetje sluznice, glavobol, kašelj, izpuščaj, bolečine v prsnem košu, astenija, faringolaringealna bolečina (orofaringealna bolečina) in zaprtost.
In those clinical trials, undesirable effects reported with equal frequency in cancer patients treated with filgrastim/chemotherapy and placebo/chemotherapy included nausea and vomiting, alopecia, diarrhoea, fatigue, anorexia (decreased appetite), mucosal inflammation, headache, cough, rash, chest pain, asthenia, pharyngolaryngeal pain (oropharyngeal pain) and constipation.
V teh kliničnih preskušanjih so bili neželeni učinki, o katerih so z enako pogostnostjo poročali pri rakavih bolnikih, zdravljenih s filgrastimom/kemoterapijo in placebom/kemoterapijo, navzea in bruhanje, alopecija, driska, utrujenost, anoreksija (zmanjšan apetit), vnetje sluznice, glavobol, kašelj, izpuščaj, bolečine v prsnem košu, astenija, faringolaringealna bolečina (orofaringealna bolečina) in zaprtost.
In those clinical trials, undesirable effects reported with equal frequency in patients treated with filgrastim/chemotherapy and placebo/chemotherapy included nausea and vomiting, alopecia, diarrhoea, fatigue, anorexia (decreased appetite), mucosal inflammation, headache, cough, rash, chest pain, asthenia, pharyngolaryngeal pain (oropharyngeal pain) and constipation.
V teh kliničnih preskušanjih so bili neželeni učinki, o katerih so enako pogosto poročali bolniki, zdravljeni s filgrastimom/kemoterapijo in placebom/kemoterapijo, navzea in bruhanje, alopecija, driska, utrujenost, anoreksija (zmanjšanje apetita), vnetje sluznice, glavobol, kašelj, izpuščaj, bolečine v prsnem košu, faringolaringealna bolečina (orofaringealna bolečina), ) in zaprtje.
In those clinical trials, undesirable effects reported with equal frequency in patients treated with filgrastim/chemotherapy and placebo/chemotherapy included nausea and vomiting, alopecia, diarrhoea, fatigue, anorexia (decreased appetite), mucosal inflammation, headache, cough, rash, chest pain, asthenia, pharyngolaryngeal pain (oropharyngeal pain) and constipation.
V teh kliničnih preskušanjih so neželeni učinki, o katerih so enako pogosto poročali pri bolnikih, zdravljenih s kemoterapijo/filgrastimom in placebo/kemoterapijo, vključevali navzeo in bruhanje, alopecijo, drisko, utrujenost, anoreksijo (zmanjšanje apetita), vnetje sluznice, glavobol, kašelj, izpuščaj, bolečino v prsih, astenijo, faringolaringealno bolečino (orofaringealno bolečino) in zaprtje.
In those patients already taking an optimised dose of vardenafil, alpha-blocker therapy should be initiated at the lowest dose.
Pri bolnikih, ki jemljejo optimalen odmerek vardenafila, je treba zdravljenje z zaviralcem adrenergičnih receptorjev alfa začeti z najmanjšim odmerkom.
In those patients in which diarrhoea led to discontinuation, it resolved after a few days of discontinuing treatment.
Pri teh bolnikih je driska izzvenela nekaj dni po prekinitvi zdravljenja.
In those patients that received > 10.6 mg/kg ribavirin (800 mg dose in typical 75 kg patient), regardless of genotype or viral load, response rates were significantly higher than in those patients that received ≤ 10.6 mg/kg ribavirin (Table 6), while response rates in patients that received > 13.2 mg/kg ribavirin were even higher.
Pri bolnikih, ki so prejeli > 10,6 mg/kg ribavirina (800 mg odmerek pri tipičnem bolniku s telesno maso 75 kg, je bil delež odziva bistveno višji kot pri tistih, ki so prejeli ≤ 10,6 mg/kg ribavirina (Preglednica 6), ne glede na genotip ali virusno obremenitev, delež odziva pri tistih, ki so prejeli > 13,2 mg/kg zdravila ribavirina, pa je bil še višji.
In those patients that received > 10.6 mg/kg ribavirin (800 mg dose in typical 75 kg patient), regardless of genotype or viral load, response rates were significantly higher than in those patients that received ≤ 10.6 mg/kg ribavirin (Table 6), while response rates in patients that received > 13.2 mg/kg ribavirin were even higher.
Pri bolnikih, ki so prejeli > 10,6 mg/kg ribavirina (800 mg odmerek pri tipičnem bolniku s telesno maso 75 kg, je bil delež odziva bistveno višji kot pri tistih, ki so prejeli ≤ 10,6 mg/kg ribavirina, ne glede na genotip ali virusno obremenitev (preglednica 6), delež odziva pri tistih, ki so prejeli > 13,2 mg/kg zdravila ribavirina, pa je bil še višji.